Physician profile
Michael Naarendorp
NPI 1740256908
$30,916.92
in general payments reported to CMS, 2019-2025
38 companies · $6,186 in 2025
The $6,186 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,181 · 2020: $1,566 · 2021: $5,181 · 2022: $5,310 · 2023: $4,004 · 2024: $4,489 · 2025: $6,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,660.30 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,095.41 | 2019-2025 | Otezla, Evenity, Enbrel |
| Aurinia Pharma U.S., INC. | $3,900.36 | 2021-2025 | Lupkynis |
| Abbvie INC. | $3,532.02 | 2019-2025 | |
| Janssen Biotech, INC. | $3,293.20 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Astrazeneca Pharmaceuticals LP | $3,222.30 | 2021-2025 | Saphnelo |
| Ucb, INC. | $1,978.43 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,638.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,316.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,112.44 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $732.83 | 2019-2025 | Taltz |
| Alexion Pharmaceuticals, INC. | $614.53 | 2020-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.96 | 2019-2025 | Ofev, Cyltezo |
| Genentech USA, INC. | $492.76 | 2019-2025 | Actemra |
| Mallinckrodt Hospital Products INC. | $429.93 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $363.20 | 2019-2025 | Orencia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Naarendorp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.